BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 19538880)

  • 1. [EGFR-blockade by antibody Cetuximab inhibits the growth of human gastric cancer xenograft in nude mice and its possible mechanism].
    Zhang J; Ji J; Yuan F; Ma T; Ye ZB; Yu YY; Liu BY; Zhu ZG
    Zhonghua Zhong Liu Za Zhi; 2009 Feb; 31(2):85-9. PubMed ID: 19538880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
    Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
    Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Impacts of Bevacizumab on vascular endothelial growth factor and Sp1 expression in gastric cancer xenografts].
    Zhou CF; Ji J; Yuan F; Yu YY; Liu BY; Zhang J; Zhu ZG
    Zhonghua Wei Chang Wai Ke Za Zhi; 2012 Feb; 15(2):180-4. PubMed ID: 22368029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced cytotoxic activity of cetuximab in EGFR-positive lung cancer by conjugating with gold nanoparticles.
    Qian Y; Qiu M; Wu Q; Tian Y; Zhang Y; Gu N; Li S; Xu L; Yin R
    Sci Rep; 2014 Dec; 4():7490. PubMed ID: 25502402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of angiogenesis by the antiepidermal growth factor receptor antibody ImClone C225 in androgen-independent prostate cancer growing orthotopically in nude mice.
    Karashima T; Sweeney P; Slaton JW; Kim SJ; Kedar D; Izawa JI; Fan Z; Pettaway C; Hicklin DJ; Shuin T; Dinney CP
    Clin Cancer Res; 2002 May; 8(5):1253-64. PubMed ID: 12006546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
    Harding J; Burtness B
    Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy.
    Ciardiello F; Bianco R; Caputo R; Caputo R; Damiano V; Troiani T; Melisi D; De Vita F; De Placido S; Bianco AR; Tortora G
    Clin Cancer Res; 2004 Jan; 10(2):784-93. PubMed ID: 14760102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced cancer therapy with the combination of EGFR and VEGFR-2 targeting in an orthotopic glioblastoma model.
    Diao Y; Tian XH; Huang YL; Chen LK; Lin XN; Zhuang ZW
    J Chemother; 2010 Dec; 22(6):407-12. PubMed ID: 21303749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells.
    Ciardiello F; Bianco R; Damiano V; Fontanini G; Caputo R; Pomatico G; De Placido S; Bianco AR; Mendelsohn J; Tortora G
    Clin Cancer Res; 2000 Sep; 6(9):3739-47. PubMed ID: 10999768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro and in vivo antitumor activity of cetuximab in human gastric cancer cell lines in relation to epidermal growth factor receptor (EGFR) expression and mutational phenotype.
    Hotz B; Keilholz U; Fusi A; Buhr HJ; Hotz HG
    Gastric Cancer; 2012 Jul; 15(3):252-64. PubMed ID: 22011788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined application of anti-VEGF and anti-EGFR attenuates the growth and angiogenesis of colorectal cancer mainly through suppressing AKT and ERK signaling in mice model.
    Ding C; Li L; Yang T; Fan X; Wu G
    BMC Cancer; 2016 Oct; 16(1):791. PubMed ID: 27729020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Growth and metastasis suppression of glioma xenografts expressing exon 4-deletion variant of epidermal growth factor receptor by monoclonal antibody CH12-mediated receptor degradation.
    Wang H; Shi B; Zhang Q; Jiang H; Hu S; Kong J; Yao M; Yang S; Li Z
    FASEB J; 2012 Jan; 26(1):73-80. PubMed ID: 21917986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cetuximab inhibits gastric cancer growth in vivo, independent of KRAS status.
    Shi M; Shi H; Ji J; Cai Q; Chen X; Yu Y; Liu B; Zhu Z; Zhang J
    Curr Cancer Drug Targets; 2014; 14(2):217-24. PubMed ID: 24467518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-epidermal growth factor receptor monoclonal antibody cetuximab inhibits EGFR/HER-2 heterodimerization and activation.
    Patel D; Bassi R; Hooper A; Prewett M; Hicklin DJ; Kang X
    Int J Oncol; 2009 Jan; 34(1):25-32. PubMed ID: 19082474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary and acquired resistance of colorectal cancer cells to anti-EGFR antibodies converge on MEK/ERK pathway activation and can be overcome by combined MEK/EGFR inhibition.
    Troiani T; Napolitano S; Vitagliano D; Morgillo F; Capasso A; Sforza V; Nappi A; Ciardiello D; Ciardiello F; Martinelli E
    Clin Cancer Res; 2014 Jul; 20(14):3775-86. PubMed ID: 24812410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity of anti-epidermal growth factor receptor monoclonal antibody C225 against glioblastoma multiforme.
    Eller JL; Longo SL; Hicklin DJ; Canute GW
    Neurosurgery; 2002 Oct; 51(4):1005-13; discussion 1013-4. PubMed ID: 12234411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts.
    Prewett MC; Hooper AT; Bassi R; Ellis LM; Waksal HW; Hicklin DJ
    Clin Cancer Res; 2002 May; 8(5):994-1003. PubMed ID: 12006511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-2 potentiation of cetuximab antitumor activity for epidermal growth factor receptor-overexpressing gastric cancer xenografts through antibody-dependent cellular cytotoxicity.
    Hara M; Nakanishi H; Tsujimura K; Matsui M; Yatabe Y; Manabe T; Tatematsu M
    Cancer Sci; 2008 Jul; 99(7):1471-8. PubMed ID: 18422755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined modality therapy of A431 human epidermoid cancer using anti-EGFr antibody C225 and radiation.
    Saleh MN; Raisch KP; Stackhouse MA; Grizzle WE; Bonner JA; Mayo MS; Kim HG; Meredith RF; Wheeler RH; Buchsbaum DJ
    Cancer Biother Radiopharm; 1999 Dec; 14(6):451-63. PubMed ID: 10850332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Influence of rosiglitazone and all-trans-retinoic acid on angiogenesis and growth of myeloma xenograft in nude mice].
    Huang HW; Chen P; Li BZ; Fu JX; Li J; Zhang XH; Liu R; Fan YY; Zhang H; Chow HC; Leung AY; Liang R
    Zhonghua Zhong Liu Za Zhi; 2012 Sep; 34(9):652-7. PubMed ID: 23159076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.